Finanzas de Corcept Therapeutics Inc (CORT)CORTCorcept Therapeutics Inc

Evaluating the bottom line, Corcept Therapeutics Incorporated maintains a gross margin of 98.41%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 16.12%, while the net margin is 16.78%. These profitability ratios, combined with a Return on Equity (ROE) of 8.23%, provide a clear picture of how effectively CORT converts its operational activities into shareholder value.

In the context of the broader market, CORT competes directly with industry leaders such as PTGX and IBRX. With a market capitalization of $9.28B, it holds a significant position in the sector. When comparing efficiency, CORT's gross margin of 98.41% stands against PTGX's 100.00% and IBRX's 99.42%. Such benchmarking helps identify whether Corcept Therapeutics Incorporated is trading at a premium or discount relative to its financial performance.

Corcept has shown strong revenue growth, with Q2 2026 revenue reported at $256.1 million, exceeding estimates by $36.1 million. The gross margin remains high at 98.41%, and the company is guiding for total revenue of $1.1B-$1.2B for 2026, reflecting a growth rate of about 51%.